Abstract
The thesis of this chapter is that the long-standing relationship between Health Canada and the pharmaceutical industry has corrupted the Canadian regulatory system. Health Canada is much more geared to the philosophy that drug regulation is primarily a commercial activity to help manufacturers get their products to the market as quickly as possible than to the idea that regulation should protect public health by ensuring that medicines that reach the market are efficacious and sufficiently safe to ensure that the benefit–harm balance is favourable. Corruption is a “loaded” term. In this case, it does not mean that bribes have been paid to Health Canada employees or that anything illegal has taken place, rather that the regulatory system has been corrupted from its primary purpose of serving the public interest to serving commercial interests. This thesis will be explored first by reviewing the history of industry–Health Canada relations and how it demonstrates an ongoing cooperative relationship whereby Health Canada has been willing to delegate regulatory responsibilities to the industry and prioritize industry’s views over those of others. The chapter then looks at how clinical trials are regulated and how the desire of industry for trials to be done quickly and as inexpensively as possible means that economic values can outweigh scientific ones. The chapter then turns to the regulatory review process and how the quality of evidence that Health Canada accepts and how quickly it reviews that information impacts on the efficacy and safety of drugs that reach the market. Promotion has a significant effect on how drugs are prescribed by physicians and the chapter critically examines how Health Canada has turned over the regulation to either industry or bodies that are closely aligned with industry. Finally, the chapter looks at the deficiencies in how safety is monitored once drugs are being prescribed, sold and used by patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anderson, J. (1977). Pressure groups and the Canadian bureaucracy. In K. Kernaghan (Ed.), Public administration in Canada: Selected readings (3rd ed., pp. 292–304). Toronto: Methuen.
Atkinson, M. M., & Coleman, W. D. (1985). Corporatism and industrial policy. In A. Cawson (Ed.), Organized interests and the state (pp. 22–44). London: Sage.
Atkinson, M. M., & Coleman, W. D. (1989). The state, business, and industrial change in Canada. Toronto: University of Toronto Press.
Auditor General of Canada. (1987). Report to the House of Commons, fiscal year ended 31 March 1987. Ottawa.
Auditor General of Canada. (2006). Report of the Auditor General of Canada to the House of Commons. Chapter 8: allocating funds to regulatory programs - Health Canada. Ottawa: Office of the Auditor General of Canada.
Auditor General of Canada. (2011). Chapter 4: Regulating pharmaceutical drugs - Health Canada. Ottawa.
ADHD drugs suspected of hurting Canadian kids. (2012, September 26). Toronto Star.
Begin plans no big changes in regulations for new drugs. (1982, October 28). Globe and Mail, 5.
Bruser, D., McLean, J., & Mendleson, R. (2015, April 24). Toronto doctor asks Health Canada about pregnancy drug, gets 212 pages of censored information. Toronto Star.
Carpenter, D. (2008). Drug-review deadlines and safety problems. New England Journal of Medicine, 359, 96–98.
Carpenter, D., Zucker, E. J., & Avorn, J. (2008). Drug-review deadlines and safety problems. New England Journal of Medicine, 358, 1354–1361.
Cocking, C. (1977, June 18). The abuse of prescription drugs. Weekend Magazine, 16–19.
Commission of Inquiry on the Pharmaceutical Industry. (1985). Report. Ottawa.
Committee Meeting Summary Reports. (2012). http://www.hc-sc.gc.ca/dhp-mps/medeff/advise-consult/eacvhp-ccevps/meet-reunion/index-eng.php. Accessed September 17 2014.
Department of Finance. (2003). Building the Canada we want. Budget 2003: Investing in Canada’s health care system. Retrieved February 15, 2004, from http://www.fin.gc.ca/budget03/booklets/bkheae.htm.
Draft Guidance Document—Triggers for Issuance of Risk Communication Documents for Marketed Health Products for Human Use. (2007). Retrieved September 26, 2013, from http://publications.gc.ca/collections/collection_2007/hc-sc/H164-48-2007E.pdf.
Drug-testing rules broken by Canadian researchers. (2014, September 16). Toronto Star.
Eggertson, L. (1997, May 28). Drug-approval process criticized. Globe and mail (pp. A1, A10).
Evans, R. (1984). Strained mercy: The economics of Canadian health care. Toronto: Butterworths.
Expert Advisory Committee on the Vigilance of Health Products. (2012). Retrieved September 17, 2014, from http://www.hc-sc.gc.ca/dhp-mps/medeff/advise-consult/eacvhp-ccevps/index-eng.php.
External Working Group on the Registration and Disclosure of Clinical Trial Information (EWG-CT). (2006). Final report: “Options for improving public access to information on clinical trials of health problems in Canada”. Ottawa: Health Canada.
Flood, C., & Dyke, P. (2012). The data divide: Managing the misalignment in Canada’s evidentiary requirements for drug regulation and funding. UBC Law Review, 45, 282–325.
Gagnon, D. (1992). Working in partnerships … drug review for the future. Ottawa.
Gagnon, M.-A., & Lexchin, J. (2008). The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine, 5(1), e1.
Groves, T. (2008). Mandatory disclosure of trial results for drugs and devices. BMJ, 336, 170.
Harper Government Launches Clinical Trials Database—New Initiatives Provide Guidance and Education on Clinical Trials for Canadians (2013). Retrieved September 7, 2014, from http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2013/2013-70-eng.php.
Health Canada. (2002). Notice of compliance with conditions (NOC/c). Ottawa.
Health Canada. (2003a). Health protective legislative renewal: Detailed legislative proposal. Ottawa.
Health Canada. (2003b). Improving Canada’s regulatory process for therapeutic products: Building the action plan: Multistakeholder consultation: Public Policy Forum.
Health Canada. (2003c). Improving Canada’s regulatory process for therapeutic products: building the action plan: Multistakeholder consultation: Public Policy Forum.
Health Canada. (2005). Clarification from Health Canada regarding the status of Iressa® (gefitinib) in Canada. Retrieved October 20, 2014, from http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/fs-fi/fact_iressa-eng.php.
Health Canada. (2006). Clinical trials: registration and disclosure of information. Retrieved December 21, 2006, from http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/proj/enreg-clini-info/2006-consult/index_e.html.
Health Canada. (2007). Departmental performance report for the period ending. Ottawa.
Health Canada. (2012a). Health product vigilance framework. Retrieved September 17, 2014, from http://www.hc-sc.gc.ca/dhp-mps/pubs/medeff/_fs-if/2012-hpvf-cvps/index-eng.php.
Health Canada. (2012b). Regulatory roadmap for health products and food. Retrieved February 15, 2015, from http://www.hc-sc.gc.ca/ahc-asc/activit/strateg/mod/roadmap-feuillederoute/rm-fr-eng.php.
Health Canada. (2017). Fee proposal for drugs and medical devices (for consultation).
Health Canada: Drugs & Health Products. (2007). Clinical trials: Registration and disclosure of information. Retrieved August 13, 2007, from http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/proj/enreg-clini-info/2005-consult/index_e.html.
Health Canada: Health Products and Food Branch. (2009). Guidance for industry: Priority review of drug submissions.
Health Canada: Health Products and Food Branch. (2017). Public release of clinical information in drug submissions and medical device applications. Ottawa.
Health Canada’s Proposal to Parliament for User Fees and Service Standards for Human Drugs and Medical Devices Programs. (2010). Retrieved September 8, 2014, from http://www.hc-sc.gc.ca/dhp-mps/finance/costs-couts/fee-propo-frais-eng.php.
Health Products and Food Branch. (1997). Guidance for industry: Good clinical practice: consolidated guideline ICH topic E6. Ottawa: Health Canada.
Health Products and Food Branch. (2004). Summary report of the inspections of clinical trials conducted in 2003/2004. Ottawa: Health Canada.
Health Products and Food Branch. (2007a). Blueprint for renewal II: Modernizing Canada’s regulatory system for health products and food. Ottawa.
Health Products and Food Branch. (2007b). Cost recovery framework: Official notice of fee proposal for human drugs and medical devices. Health Canada.
Health Products and Food Branch. (2007c). Inaugral summary meeting report—Expert Advisory Committee on the Vigilance of Health Products—November 27–28, 2007. Retrieved September 17, 2014, from http://www.hc-sc.gc.ca/dhp-mps/medeff/advise-consult/eacvhp-ccevps/meet-reunion/nov-nov-07-eng.php.
Health Products and Food Branch Inspectorate. (2012). Summary report of inspections of clinical trials conducted from April 2004 to March 2011.
Herder, M. (2012). Unlocking Health Canada’s cache of trade secrets: Mandatory disclosure of clinical trial results. CMAJ, 184, 194–199.
Herder, M. (2014). Denaturalizing transparency in drug regulation. McGill Journal of Law and Health, 8(2), S57–S143.
Herder, M., Gibson, E., Graham, J., Lexchin, J., & Mintzes, B. (2014). Regulating prescription drugs for patient safety: Does Bill C-17 go far enough? CMAJ, 186, E287–E292.
Hirsch, L. (2004). Randomized clinical trials: What gets published, and when? CMAJ, 170, 481–483.
House of Commons Debates: Official Report. (1962). Ottawa: Queen’s Printer.
House of Commons of Canada. (2013). Bill C-17: An act to amend the Food and Drugs Act, first reading, December 6, 2013.
House of Commons of Canada. (2014). Bill C-17: An act to amend the Food and Drugs Act, as passed by the House of Commons June 16, 2014.
House of Commons Standing Committee on Health. (2004). Opening the medicine cabinet: First report on health aspects of prescription drugs. Ottawa.
How a suspect arthritis drug evaded government checks. (1982, October 25). Montreal Gazette, A-1, A-6.
Innovative Medicines Canada. (2016). Code of ethical practices. Retrieved October 18, 2016, from http://innovativemedicines.ca/wp-content/uploads/2015/06/IMC_Code_EN.pdf.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1996). ICH harmonised tripartite guideline: Guideline for good clinical practice E6(R1). Retrieved September 6, 2014, from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
Kermode-Scott, B. (2004). Canadian health ministry faces criticism for its secrecy. BMJ, 328, 1222.
Kim, E., Hirsh, V., Mok, T., Socinski, M., Gervais, R., Wu, Y.-L., et al. (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet, 372, 1809–1818.
KPMG Consulting LP. (2000). Report volume 1: Review of the Therapeutic Products Programme cost recovery initiative. Ottawa.
Law, M. (2014). The characteristics and fulfillment of conditional prescription drug approvals in Canada. Health Policy, 116, 154–161.
Lexchin, J. (1984). The real pushers: A critical analysis of the Canadian drug industry. Vancouver: New Star Books.
Lexchin, J. (2007). Notice of compliance with conditions: A policy in limbo. Healthcare Policy, 2, 114–122.
Lexchin, J. (2012). New drugs and safety: What happened to new active substances approved in Canada between 1995 and 2010? Archive of Internal Medicine, 172, 1680–1681.
Lexchin, J. (2013). How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009. Open Medicine, 8, e14–e19.
Lexchin, J. (2014). Postmarket safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy. British Journal of Clinical Pharmacology, 79, 847–859.
Lexchin, J. (2015). Health Canada’s use of its priority review process for new drugs: A cohort study. British Medical Journal Open, 5, e006816.
Lexchin, J., & Mintzes, B. (2014). A compromise too far: A review of Canadian cases of direct-to-consumer advertising regulation. International Journal of Risk and Safety in Medicine, 26, 213–225.
Marketed Health Products Directorate. (2004). How adverse reaction information on health products is used. Ottawa.
Mintzes, B., Lexchin, J., Sutherland, J., Beaulieu, M.-D., Wilkes, M., Durrieu, G., et al. (2013). Pharmaceutical sales representatives and patient safety: A comparative prospective study of information quality in Canada, France and the United States. Journal of General Internal Medicine, 28, 1368–1375.
Morrision, A. (1975). The Canadian approach to food and drug regulations. Food, Drug, Cosmetic Law Journal, 30, 632–643.
Pharmaceutical Adverising Advisory Board. (1986). PAAB regulations amending the food and drug regulations (Public Release of Clinical Information): Regulatory impact analysis statement code of advertising acceptance. Pickering: PAAB.
Pharmaceutical Advertising Advisory Board. (2013). Code of advertising acceptance. Retrieved September 13, 2014, from http://www.paab.ca/paab-code.htm.
Pharmaceutical submission and application review fees as of April 1, 2014. (2014). Retrieved September 8, 2014, from http://www.hc-sc.gc.ca/dhp-mps/finance/fees-frais/pharma-eng.php.
Potter, R. (1966). Prescription drugs: The changing response of Canada’s Food and Drug Act (Part 4). Canadian Pharmaceutical Journal, 99(2), 9–12, 39.
Raison, A. (1989). The evolution of standards for pharmaceutical advertising in Canada. Pickering: Pharmaceutical Advertising Advisory Board.
Regulations Amending the Food and Drug Regulations (Public Release of Clinical Information): regulatory impact analysis statement. (2017). Canada Gazette, 151(49).
Regulations Amending the Food and Drugs Regulations (1024—Clinical trials). (2000). Canada Gazette, 134(4), 227–260.
Re: ADHD drugs suspected of hurting Canadian kids, Sept. 26. (2012, September 27). Toronto Star.
Rhines, J., & Robinson, W. (2014). Standing Senate Committee on Social Affairs, Science and Technology, Bill C-17: Evidence. Retrieved October 19, 2014, from http://www.parl.gc.ca/HousePublications/Publication.aspx?Language=E&Mode=1&DocId=6676418.
Rx&D. (2003). Improving health through innovation: A new deal for Canadians. Ottawa.
Rx&D. (2004). Drug approval times…a question of access for Canadian patients to new and innovative therapies. Ottawa.
Rx&D (2010). Where we stand: detailing. (pp. 2). Ottawa: Canada’s Research-Based Pharmaceutical Companies
Schafer, A. (2011, January 19). A bitter pill: Consultations on drug safety appear to be stacked in favour of industry, which could be bad news for the public, writes Arthur Schafer. Ottawa Citizen.
Shuchman, M. (2008). Clinical trials regulation—How Canada compares. CMAJ, 179, 635–638.
Shuchman, M. (2013). Health Canada’s new clinical trials database should be mandatory, says expert. CMAJ, 185, 946.
Spurling, G., Mansfield, P. R., Montgomery, B., Lexchin, J., Doust, J., Othman, N., et al. (2010). Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Medicine, 7, e1000352.
Standing Senate Committee on Social Affairs Science and Technology. (2014). Evidence. Retrieved October 27, 2014, from http://www.parl.gc.ca/content/sen/committee/412/SOCI/51634-E.HTM.
Svensson, S., Menkes, D., & Lexchin, J. (2013). Surrogate outcomes in clinical trials: A cautionary tale. JAMA Internal Medicine, 173, 611–612.
Task Force on Program Review. (1986). Improved program delivery: Health and sports. Ottawa.
Thatcher, N., Chang, A., Parikh, P., Pereira, J., Ciuleanu, T., von Pawel, J., et al. (2005). Gefitinib plus best supportive care in previous treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lund Cancer). Lancet, 366, 1527–1537.
The Public Policy Forum. (2003). Improving Canada’s regulatory process for therapeutic products.
Towards a globally competitive research-based pharmaceutical sector. A submission to the steering group on the federal government’s prosperity initiative (1992). Ottawa.
Turner, C. (2012, September 27). ADHD drugs suspected of hurting canadian kids. Toronto Star.
Update and response to OAG recommendations for the regulation of pharmaceutical drugs in fall 2011. (2013). Retrieved September 9, 2014, from http://www.hc-sc.gc.ca/ahc-asc/pubs/hpfb-dgpsa/oag-bvg-eng.php.
Villemure, C. (2005). Health product safety board: Progress update: presentation to ACM.
WMA Declaration of Helsinki—Ethical principles for medical research involving human subjects (2008). Retrieved September 15, 2013, from http://www.wma.net/en/30publications/10policies/b3/.
Working Group on Drug Submission Review. (1987). Memorandum to the Minister (the Stein Report). Ottawa.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Lexchin, J. (2020). Corruption of the Canadian Drug Regulatory System. In: Çalıyurt, K. (eds) Integrity, Transparency and Corruption in Healthcare & Research on Health, Volume I. Accounting, Finance, Sustainability, Governance & Fraud: Theory and Application. Springer, Singapore. https://doi.org/10.1007/978-981-15-1424-1_5
Download citation
DOI: https://doi.org/10.1007/978-981-15-1424-1_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-1423-4
Online ISBN: 978-981-15-1424-1
eBook Packages: Religion and PhilosophyPhilosophy and Religion (R0)